Evidence map›Paper›PMID 32691747›Full record

ArticleIET nanobiotechnology2020

Iron oxide/gold nanoparticles-decorated reduced graphene oxide nanohybrid as the thermo-radiotherapy agent.

Kave Moloudi, Hadi Samadian, Mehdi Jaymand, Ehsan Khodamoradi, Mojtaba Hoseini-Ghahfarokhi, Farshid Fathi

Abstract read
In one paragraph

Article in IET nanobiotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kave MoloudiDepartment of Radiology and Nuclear Medicine, Alley School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hadi SamadianNano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mehdi JaymandNano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Ehsan KhodamoradiDepartment of Radiology and Nuclear Medicine, Alley School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. eh_medph@yahoo.com.
Mojtaba Hoseini-GhahfarokhiDepartment of Radiology and Nuclear Medicine, Alley School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Farshid FathiDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main focus of the current study is the fabrication of a multifunctional nanohybrid based on graphene oxide (GO)/iron oxide/gold nanoparticles (NPs) as the combinatorial cancer treatment agent. Gold and iron oxide NPs formed on the GONPs via the in situ synthesis approach. The characterisations showed that gold and iron oxide NPs formed onto the GO. Cell toxicity assessment revealed that the fabricated nanohybrid exhibited negligible toxicity against MCF-7 cells in low doses (<50 ppm). Temperature measurement showed a time and dose-dependent heat elevation under the interaction of the nanohybrid with the radio frequency (RF) wave. The highest temperature was recorded using 200 ppm concentration nanohybrid during 40 min exposure. The combinatorial treatments demonstrated that the maximum cell death (average of 53%) was induced with the combination of the nanohybrid with RF waves and radiotherapy (RT). The mechanistic study using the flow cytometry technique illustrated that early apoptosis was the main underlying cell death. Moreover, the dose enhancement factor of 1.63 and 2.63 were obtained from RT and RF, respectively. To sum up, the authors' findings indicated that the prepared nanohybrid could be considered as multifunctional and combinatorial cancer therapy agents.

Indexed as

Antineoplastic AgentsApoptosisCell SurvivalGoldGraphiteHumansHyperthermia, InducedMagnetic Iron Oxide NanoparticlesMCF-7 CellsNanostructuresRadiotherapyAntineoplastic AgentsGoldgraphene oxideGraphite

Identifiers

PMID32691747
PMCPMC8676201

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.